EUVIMEDEUVIMED entdecken
Crossref

A Consensus Statement on the Administration of Systemic Bevacizumab in Patients with Recurrent Respiratory Papillomatosis

Simon R Best iD, Jonathan M Bock iD, Nicole B Fowler, Eric H Raabe, Adam M Klein, Theodore W Laetsch, Kim McClellan, Rico N P M Rinkel, Nabil F Saba, Douglas R Sidell iD, James B Tansey, David E Tunkel iD und 2 weitere

The Laryngoscope · 2024-12 · 134 (12) · 5041-5046

DOI: 10.1002/lary.31670 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, online erschienen am 03.08.2024. Verfasst von Simon R Best und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A. Hauptthemen laut MEDLINE: Bevacizumab, Respiratory Tract Infections, Papillomavirus Infections. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: RRPF as a Chan Zuckerberg Initiative (CZI) Rare as One-funded Organization, Chan Zuckerberg Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To provide detailed guidance on the administration of systemic bevacizumab in patients with recurrent respiratory papillomatosis (RRP) based on a detailed review of the scientific literature and a consensus of experts with real‐world clinical experience.

Methods

A bevacizumab consensus working group ( N = 10) was composed of adult and pediatric otolaryngologists, adult and pediatric oncologists, and a representative from the RRP Foundation (RRPF), all with experience administering systemic bevacizumab in patients with RRP. After extensive review of the medical literature, a modified Delphi method‐based survey series was utilized to establish consensus on the following key areas: clinical and patient characteristics ideal for treatment candidacy, patient perspective in treatment decisions, treatment access, initial dosing, monitoring, guidelines for tapering and discontinuation, and reintensifying therapy.

Results

Seventy‐nine statements were identified across nine critical domains, and 45 reached consensus [clinical benefits of bevacizumab (3), patient and disease characteristics for treatment consideration (7), contraindications for treatment (3), shared decision‐making (incorporating the patient perspective) (5), treatment access (3), initial dosing and administration (8), monitoring (7), tapering and discontinuation (6), and reintensification (3)].

Conclusion

This consensus statement provides the necessary guidance for clinicians to initiate systemic administration of bevacizumab and represents a potential paradigm shift toward nonsurgical treatment options for patients with RRP. Level of Evidence 5 Laryngoscope , 134:5041–5046, 2024

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabRespiratory Tract InfectionsPapillomavirus InfectionsHumansDelphi TechniqueAngiogenesis InhibitorsAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

Avastinadministrationconsensussystemic bevacizumab

Substanzen

BevacizumabAngiogenesis InhibitorsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.
  • Department of Otolaryngology and Communication Sciences, Medical College of Wisconsin, Milwaukee, Wisconsin, U.S.A.
  • Recurrent Respiratory Papillomatosis Foundation, Lawrenceville, New Jersey, U.S.A.
  • Division of Pediatric Oncology, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.
  • Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland, U.S.A.
  • Department of Otolaryngology-Head and Neck Surgery, Emory Voice Center, Emory University School of Medicine, Atlanta, Georgia, U.S.A.

ORCID-Profile: Simon R Best, Jonathan M Bock, Douglas R Sidell, David E Tunkel

Förderung

  • RRPF as a Chan Zuckerberg Initiative (CZI) Rare as One-funded Organization
  • Chan Zuckerberg Initiative

Zitieren

APA

Best, S. R., Bock, J. M., Fowler, N. B., Raabe, E. H., Klein, A. M., Laetsch, T. W., McClellan, K., Rinkel, R. N. P. M., Saba, N. F., Sidell, D. R., Tansey, J. B., Tunkel, D. E., Young, G. D., & Zur, K. B. (2024). A Consensus Statement on the Administration of Systemic Bevacizumab in Patients with Recurrent Respiratory Papillomatosis. The Laryngoscope, 134(12), 5041-5046. https://doi.org/10.1002/lary.31670

Vancouver

Best SR, Bock JM, Fowler NB, Raabe EH, Klein AM, Laetsch TW, et al. A Consensus Statement on the Administration of Systemic Bevacizumab in Patients with Recurrent Respiratory Papillomatosis. The Laryngoscope. 2024;134(12):5041-5046. doi:10.1002/lary.31670

BibTeX
@article{Best2024,
  author = {Best, Simon R and Bock, Jonathan M and Fowler, Nicole B and Raabe, Eric H and Klein, Adam M and Laetsch, Theodore W and McClellan, Kim and Rinkel, Rico N P M and Saba, Nabil F and Sidell, Douglas R and Tansey, James B and Tunkel, David E and Young, Geoffrey D and Zur, Karen B},
  title = {A Consensus Statement on the Administration of Systemic Bevacizumab in Patients with Recurrent Respiratory Papillomatosis},
  journal = {The Laryngoscope},
  year = {2024},
  volume = {134},
  number = {12},
  pages = {5041--5046},
  doi = {10.1002/lary.31670}
}
Kostenlos starten →